RxDoctor Payments Data

Arun Narang, MD

Internal Medicine · McHenry, ILNPI 1952469215

Payments from drug & device makers

$1,279in general payments, 2019–2025

Across 17 payments — averaging $75.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$399
  • Sanofi-aventis U.S. LLC$235
  • AstraZeneca$160
  • Amgen$148
  • Lexicon Pharmaceuticals, Inc.$106
  • Medtronic$102
  • plus $130 from 3 others

What the payments were for

  • Food & beverage$1,26499%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,279 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$329,136
Medicare patients
519
Services billed
4,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide254$306,223
JardianceEmpagliflozin190$212,145
FarxigaDapagliflozin Propanediol168$159,200
EliquisApixaban276$143,784
Trelegy ElliptaFluticasone/Umeclidin/Vilanter166$131,362
XareltoRivaroxaban149$121,223
RybelsusSemaglutide79$114,108
EntrestoSacubitril/Valsartan62$61,048
MyrbetriqMirabegron80$50,873
MounjaroTirzepatide37$40,711
TrulicityDulaglutide23$39,971
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr55$29,519
WegovySemaglutide19$25,303
Breo ElliptaFluticasone/Vilanterol27$21,472
Stiolto RespimatTiotropium Br/Olodaterol Hcl39$20,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$399$445,635352 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr$89$243,012242 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$28$188,189265 claims
AstraZenecaFarxiga, Breztri Aerosphere$160$173,240190 claims
NovartisEntresto$12$61,04862 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in McHenry

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →